AUTHOR=Ding Kejun , Shi Zhewei , Qian Caizhen , Yang Xuan 

TITLE=Higher Plasma Pentraxin-3 Level Predicts Adverse Clinical Outcomes in Patients With Coronary Artery Disease: A Meta-Analysis of Cohort Studies

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=Volume 8 - 2021

YEAR=2022

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.726289

DOI=10.3389/fcvm.2021.726289

ISSN=2297-055X

ABSTRACT=Background: Association between plasma pentraxin-3 (PTX-3) and clinical outcomes in patients with coronary artery disease (CAD) remains not fully determined. An updated meta-analysis of cohort studies was performed to systematically evaluate the association.

Methods: Cohort studies evaluating the association between plasma PTX-3 and adverse outcomes (mortality and major adverse cardiovascular events [MACEs]) in adults with CAD were identified by systematic search of PubMed, Embase, and Web of Science databases. Only studies with multivariate analysis were included. A random-effects model incorporating the potential intra-study heterogeneity was used for the meta-analysis.

Results: Sixteen studies including 11007 patients were included. Pooled results showed that patients with highest level of PTX-3 were independently associated with higher risk of mortality (adjusted risk ratio [RR]: 2.09, 95% confidence interval [CI]: 1.60 to 2.74, P<0.001; I2=50%) and MACEs (adjusted RR: 1.80, 95% CI: 1.43 to 2.28, P<0.001; I2=49%). Subgroup analyses showed that the associations between PTX-3 and poor prognosis in CAD were consistent in patients with ST-segment elevation myocardial infraction, non-ST-segment elevation acute coronary syndrome, and stable CAD (P all < 0.05 for each subgroup). Besides, the association between PTX-3 and increased incidence of mortality and MACEs were consistent in short-term (within one year) and long-term (over one year) studies, and in studies with or without adjustment of C-reactive protein (CRP, P all < 0.05 for each subgroup).

Conclusions: Higher plasma PTX-3 is associated with poor prognosis in patients with CAD, which may be independent of the CAD subtype, follow-up durations, and adjustment of CRP.